Tildrakizumab Prefilled Syringe for Psoriasis

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
University of California, San Francisco, San Francisco, CA
Psoriasis+1 More
Tildrakizumab Prefilled Syringe - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study how well an experimental drug works in people with psoriasis. The purpose of this trial is to test the safety and effectiveness of Tildrakizumab Prefilled Syringe in the treatment of Psoriasis. This is a Phase 3 clinical trial, which means that it is the last stage of testing before the drug is submitted for FDA approval. Because this trial is double-blinded, neither the patients nor the doctors will know who is receiving the active drug and who is receiving the placebo. The trial will involve 300 patients with moderate to severe Psoriasis. It will last for 16 weeks.The trial is being conducted by Sun Pharma, the manufacturer of Tildrak

Eligible Conditions

  • Psoriasis
  • Psoriasis Vulgaris (Plaque Psoriasis)

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Psoriasis

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Baseline, 3 months

Baseline, 3 months
Change in Psoriasis Area and Severity Index (PASI) Score at baseline and 3 months of treatment

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Psoriasis

Trial Design

1 Treatment Group

Tildrakizumab treatment
1 of 1
Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Tildrakizumab Prefilled Syringe · No Placebo Group · Phase 4

Tildrakizumab treatment
Drug
Experimental Group · 1 Intervention: Tildrakizumab Prefilled Syringe · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 3 months
Closest Location: University of California, San Francisco · San Francisco, CA
Photo of San Francisco 1Photo of San Francisco 2Photo of San Francisco 3
2008First Recorded Clinical Trial
6 TrialsResearching Psoriasis
691 CompletedClinical Trials

Who is running the clinical trial?

Sun Pharmaceutical Industries LimitedIndustry Sponsor
59 Previous Clinical Trials
13,493 Total Patients Enrolled
13 Trials studying Psoriasis
2,829 Patients Enrolled for Psoriasis
University of California, San FranciscoLead Sponsor
2,246 Previous Clinical Trials
11,473,130 Total Patients Enrolled
13 Trials studying Psoriasis
328 Patients Enrolled for Psoriasis
Raymond Cho, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
40 Total Patients Enrolled
1 Trials studying Psoriasis
40 Patients Enrolled for Psoriasis

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have moderate-severe psoriasis or > 5% body surface area affected.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.